Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment

Drugs and Aging

Volumn 18, Issue 9, 2001, Pages 685-716

  Halliwell, B ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOMORPHINE; CAROTENOID; FLAVONOID; FREE RADICAL; GLUTATHIONE; LIPID PEROXIDE; MANGANESE SUPEROXIDE DISMUTASE; NITECAPONE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SUPEROXIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN OXYGEN CONSUMPTION; DEGENERATIVE DISEASE; ELECTRON TRANSPORT; IRON METABOLISM; LIPID PEROXIDATION; MICROGLIA; MITOCHONDRIAL RESPIRATION; NEUROTRANSMISSION; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

EID: 0034796353     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118090-00004     Document Type: Review

References (414)

1. NADPH oxidase: An update
2. Oxidative stress and nuclear factor-κB activation
3. Inhibition of nitric oxide synthase as a potential therapeutic target
4. ·-), superoxide dismutases, and related matters
5. On the limited ability of superoxide to release iron from ferritin
6. The role of iron-sulfur clusters in in vivo hydroxyl radical production
7. Hydroperoxide metabolism in mammalian organs
8. Hypoxia, reactive oxygen, and cell injury
9. Methionine residues may protect proteins from critical oxidative damage
10. Redox regulation of the caspases during apoptosis
11. Caspases are reversibly inactivated by hydrogen peroxide
12. Hydrogen peroxide in the human body
13. 2 detected in healthy volunteers
14. Formation of hydroxyl radicals in biological systems: Does myoglobin stimulate hydroxyl radical formation from hydrogen peroxide?
15. Iron release from metmyoglobin, methaemoglobin and cytochrome c by a system generating hydrogen peroxide
16. Nutrition and development: Other micronutrients' effect on growth and cognition
17. Oxygen toxicity, oxygen radicals, transition metals and disease
18. Role of free radicals and catalytic metal ions in human disease: An overview
19. Vitamin C: Poison, prophylactic or panacea?
20. Chemical determination of oxidative DNA damage by gas chromatography-mass spectrometry
21. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis
22. Mutagenicity and repair of oxidative DNA damage: Insights from studies using defined lesions
23. Genotoxicity of ribo- and deoxyribonucleosides of 8-hydroxyguanine, 5-hydroxycytosine, and 2-hydroxyadenine: Induction of SCE in human lymphocytes and mutagenicity in Salmonella typhimurium TA 100
24. The mutations induced by oxidatively damaged nucleotides, 5-formyl-dUTP and 5-hydroxy-dCTP, in Escherichia coli
25. Biochemistry and pathology of radical-mediated protein oxidation
26. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
27. Cytotoxic and genotoxic potential of dopamine
28. Autoxidation versus covalent binding of quinines as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
29. Manganese ions, oxidation reactions and the superoxide radical
30. Endogenous nitric oxide synthesis: Biological functions and pathophysiology
31. Role of nitric oxide in the control of mitochondrial function
32. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly
33. Nitric oxide and peroxynitrire: The ugly, the uglier and the not so good
34. Biological tyrosine nitration: A pathophysiological function of nitric oxide and reactive oxygen species
35. Tyrosine nitration: Localization, quantification, consequences for protein function and signal transduction
36. Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation
37. Hemoglobin-based blood substitutes and the hazards of blood radicals
38. A review of hemoglobin and the pathogenesis of cerebral vasospasm
39. Promotion of oxidative damage to arachidonic acid and alpha 1-antiproteinase by anti-inflammatory drugs in the presence of the haem proteins myoglobin and cytochrome c
40. Effects of oxyradicals on oxymyoglobin: Deoxygenation, haem removal and iron release
41. Heme-oxygenase-1 induction in glia throughout rat brain following experimental subarachnoid hemorrhage
42. Haem oxygenase shows pro-oxidant activity in microsomal and cellular systems: Implications for the release of low-molecular-mass iron
43. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice
44. Mitochondrial disease in superoxide dismutase 2 mutant mice
45. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase
46. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase
47. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury
48. The use of transgenic and mutant mice to study oxygen free radical metabolism
49. Ovarian function in superoxide dismutase 1 and 2 knockout mice
50. Extracellular superoxide dismutase: A regulator of nitric oxide bioavailability
51. Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia
52. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia
53. Extracellular superoxide dismutase deficiency worsens outcome from focal cerebral ischaemia in the mouse
54. Impairment of long-term potentiation and associated memory in mice that overexpress extracellular superoxide dismutase
55. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin
56. Thioredoxin reductase
57. Redox regulation of cellular activation
58. Cellular and subcellular heterogeneity of glutathione metabolism and transport in rat kidney cells
59. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene
60. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha
61. Enrichment and functional reconstitution of glutathione transport activity from rabbit kidney mitochondria: Further evidence for the role of the dicarboxylate and 2-oxoglutarate carriers in mitochondrial glutathione transport
62. The antioxidants of human extracellular fluids
63. Non-caeruloplasmin copper and ferroxidase activity in mammalian serum: Ferroxidase activity and phenanthroline-detectable copper in human serum in Wilson's disease
64. Mineralization in ferritin: An efficient means of iron storage
65. Mechanisms for protection against copper toxicity
66. Dynamics of the cytosolic chelatable iron pool of K562 cells
67. The cellular labile iron pool and intracellular ferritin in K562 cells
68. Determination of the chelatable iron pool of isolated rat hepatocytes by digital fluorescence microscopy using the fluorescent probe, phen green SK
69. Bleomycin-detectable iron in brain tissue
70. Intense oxidative DNA damage promoted by L-dopa and its metabolites: Implications for neurodegenerative disease
71. Assay using brain homogenate for measuring the antioxidant activity of biological fluids
72. Regional lipid peroxidation in rat brain in vitro: Possible role of endogenous iron
73. Biokinetics of vitamin E
74. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats
75. Role of coenzyme Q and superoxide in vitamin E cycling
76. The antioxidant and biological properties of the carotenoids
77. Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature
78. Density of the human crystalline lens is related to the macular pigment carotenoids, lutein and zeaxanthin
79. Lycopene as the most efficient biological carotenoids singlet oxygen quencher
80. Singlet oxygen mediates the UVA-induced generation of the photoaging-associated mitochondrial common deletion
81. Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants
82. The gastrointestinal tract: A major site of antioxidant action?
83. Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies
84. Polyphenolic antioxidants in fruit juice; urinary excretion and effects on biological markers for antioxidative status
85. The isoprostanes: Unique bioactive products of lipid peroxidation
86. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo
87. DNA repair pathways and cancer prevention
88. Degradation of oxidized proteins in mammalian cells
89. Tissue-specific functions of individual glutathione peroxidases
90. 2-induced senescent-growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication
91. Antioxidant defence mechanisms: From the beginning to the end (of the beginning)
92. Inter- and intra-individual variation in plasma and red blood cell vitamin E after supplementation
93. Symposium overview: The role of genetic polymorphism and repair deficiencies in environmental disease
94. Polymorphisms in the human DNA repair gene XPF
95. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress
96. Oxidative stress, human genetic variation, and disease
97. 2-isoprostanes are not correlated in healthy human subjects
98. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster
99. The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans
100. The gerontogenes age-1 and daf-2 determine metabolic rate potential in aging Caenorhabditis elegans
101. Aging and resistance to oxidative damage in Caenorhabditis elegans
102. Extension of life-span with superoxide dismutase/catalase mimetics
103. Oxidative stress, caloric restriction, and aging
104. Caloric restriction attenuates dityrosine cross-linking of cardiac and skeletal muscle proteins in aging mice
105. Aging, chromatin and food restriction: Connecting the dots
106. Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse
107. Mitochondria, oxidative stress and aging
108. A method for detecting abasic sites in living cells: Age-dependent changes in base excision repair
109. DNA-damage and DNA-repair in aging brain
110. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication
111. Decreased proteasome-mediated degradation in T cells from the elderly: A role in immune senescence
112. Possible involvement of proteasome inhibition in aging: Implications for oxidative stress
113. Age-related changes in the 20S and 26S proteasome activities in the liver of male F344 rats
114. Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle
115. Proteasomal dysfunction: A primary event in neurodegeneration that leads to nitrative and oxidative stress and subsequent cell death
116. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain
117. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease
118. Concurrent increase of oxidative DNA damage and lipid peroxidation together with mitochondrial DNA mutation in human lung tissues during aging: Smoking enhances oxidative stress on the aged tissues
119. Retarding effect of dietary restriction on the accumulation of 8-hydroxy-2′-deoxyguanosine in organs of Fisher 344 rats during aging
120. Neurotoxicity risk assessment of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) as a synthetic impurity of drugs
121. Antagonistic effect of melatonin against cyanide-induced seizures and acute lethality in mice
122. 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid
123. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
124. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases
125. Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice
126. The role of nitric oxide in neurodegeneration: Potential for pharmacological intervention
127. Common mechanisms of oxidative damage in chronic neurodegenerative conditions: Potential points of therapeutic intervention
128. Oxidative alterations in Alzheimer's disease
129. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species
130. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat
131. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione
132. Cellular distribution of ferritin subunits in postnatal rat brain
133. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains
134. Regional distribution of iron, transferrin, ferritin and oxidatively-modified proteins in young and aged Fischer 344 rat brains
135. Reduction in nitric synthase activity with development of an epileptogenic focus induced by ferric chloride in the rat brain
136. Iron and oxygen radicals in brain
137. Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid
138. Variations in dietary iron alter brain iron metabolism in developing rats
139. Transferrin and transferrin receptor function in brain barrier systems
140. 4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease
141. A role for 4-hydroxynonenal, an aldehyde product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide
142. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis
143. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial mempory in rats
144. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype
145. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis
146. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system
147. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease
148. Distribution of hydroxynonenal-modified proteins in the kainate-lesioned rat hippocampus: Evidence that hydroxynonenal formation precedes neuronal cell death
149. The alpha-ketoglutarate dehydrogenase complex
150. Dopamine turnover and glutathione oxidation: Implications for Parkinson disease
151. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
152. Role of MAO A and B in neurotransmitter metabolism and behavior
153. Oxidative modification of glutamine synthetase by amyloid beta peptide
154. Regional distribution of catalase in the adult rat brain
155. Microperoxisome distribution in the central nervous system of the rat
156. Hydrogen peroxide production by rat brain in vivo
157. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death
158. Species differences in the generation of reactive oxygen species by microglia
159. Cerebrospinal fluid nitric oxide levels in childhood bacterial meningitis
160. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course
161. Metabolism of xenobiotics in the central nervous system: Implications and challenges
162. Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system
163. Cytochrome P4502E (CYP2E) in brain: Constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization
164. 2-MPTP on serotonergic and noradrenergic nerve terminals
165. Attenuation of acute and chronic damage following traumatic brain injury in copper, zinc-superoxide dismutase transgenic mice
166. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischaemia and reperfusion
167. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxy-methamphetamine (Ecstasy)
168. Overexpressing Cu/Zn superoxidase dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease
169. 2, 4-HNE or serum deprivation: Potentiation of injury by ALS-related mutant SODs and protection by bcl-2
170. Down-regulation of Cu/Zn-superoxide dismutase causes apoptotic death in PC12 neuronal cells
171. Glutathione deficiency leads to mitochondrial damage in brain
172. Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischaemia/reperfusion damage
173. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate 3-nitropropionic acid, and MPTP
174. Differential expression of peroxiredoxin subtypes in human brain cell types
175. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage
176. Cellular clones and transgenic mice overexpressing copper-zinc superoxide dismutase: Models for the study of free radical metabolism and aging
177. Down's syndrome: A pathology involving the lack of balance of reactive oxygen species
178. Cell damage by excess CuZnSOD and Down's syndrome
179. Effect of overexpression of wild-type and mutant CuZnSODs on oxidative damage and antioxidant defences: Relevance to Down's syndrome and familial ALS
180. Molecular manipulations of extracellular superoxide dismutase: Functional importance for learning
181. Glutathione metabolism in brain
182. The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells
183. Changes in glutathione in the hippocampus of rats injected with kainate: Depletion in neurons and upregulation in glia
184. Contributing mechanisms for cysteine excitotoxicity in cultured cerebellar granule cells
185. Neurotoxicity of cysteine: Interaction with glutamate
186. Model for transport in the central nervous system
187. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity
188. Ascorbate transport and intracellular concentration in cerebral astrocytes
189. The suppression of iron release from activated myoglobin by physiological electron donors and by desferrioxamine
190. Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols, and ubiquinones
191. Neurochemical, neurophysiological, and neuropathological studies in vitamin E deficiency
192. Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emisson tomographic studies
193. Alpha-tocopherol concentrations of the nervous system and selected tissues of adult dogs fed three levels of vitamin E
194. Nigral dopaminergic cell loss in vitamin E deficient rats
195. Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians, and controls
196. Plasma antioxidants and longevity: A study on healthy centenarians
197. Serum levels of α-tocopherol (vitamin E) in Parkinson's disease
198. Alpha-tocopherol levels in brain are not altered in Parkinson's disease
199. 10 deficiency
200. 10 administration and its potential for treatment of neurodegenerative diseases
201. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedrich's ataxia
202. Cis-trans isomers of lycopene and beta-carotene in human serum and tissues
203. Distribution and antioxidant activity of a palm oil carotene fraction in rats
204. Synthetic flavonoids cross the placenta in the rat and are found in fetal brain
205. Cholinesterase inhibitors and Gingko extract: Are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration
206. 2+-loaded brain neurons
207. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba
208. Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferolic acid
209. Expression of the ceruloplasmin gene in the human retina and brain: Implications for a pathogenic model in aceruloplasminemia
210. Increased lipid peroxidation in the brains of aceruloplasminemia patients
211. CSF in Alzheimer's disease: Studies on blood-brain barrier function and intrathecal protein synthesis
212. Hypohaptoglobinemia associated with familial epilepsy
213. Regulation of the synthesis of brain metallothioneins
214. CNS wound healing is severely depressed in metallothionein I- and II-deficient mice
215. Expression and regulation of brain metallothionein
216. Alzheimer's disease, beta-amyloid protein and zinc
217. Heme oxygenase: Recent advances in understanding its regulation and role
218. Oxidative stress hypothesis in Alzheimer's disease
219. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice
220. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of κ induced by 4-hydroxy-2-nonenal modification
221. Hemoglobin and iron-evoked oxidative stress in the brain: Protection by bile pigments, manganese and S-nitrosoglutathione
222. Purification and properties of the 26S proteasome from the rat brain: Evidence for its degradation of myelin basic protein in a ubiquitin-dependent manner
223. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain
224. Carnosine-related dipeptides in the mammalian brain
225. Carnosine, homocarnosine and anserine: Could they act as antioxidants in vivo?
226. Identification of hydrazine in commercial preparations of carnosine and its influence on carnosine's antioxidative properties
227. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain
228. Endogenous mechanisms of neuroprotection: Role of zinc, copper, and carnosine
229. Enzymatic protection against peroxidative damage in isolated brain capillaries
230. Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat
231. The preventive role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia
232. Drug antioxidant effects: A basis for drug selection?
233. Increased oxidative stress brought on by pro-inflammatory cytokines in neurodegenerative processes and the protective role of nitrone-based free radical traps
234. Novel quinolinic derivatives as centrally active antioxidants
235. N-Acetylcysteine delays age-associated memory empairment in mice: Role in synaptic mitochondria
236. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy
237. Chroman amide 12P: Inhibition of lipid peroxidation and protection against learning and memory impairment
238. Incorporation of sodium channel blocking and free radical scavenging into a single drug, AM-36, results in profound inhibition of neuronal apoptosis
239. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischaemia in a primate species
240. Deprenyl and desmethyselgiline protect mescencephalic neurons from toxicity induced by glutathione depletion
241. Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties
242. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: A possible antioxidant strategy
243. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
244. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
245. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease
246. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
247. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra
248. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons
249. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease
250. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease
251. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine and o,o′-dityrosine in brain tissue of MPTP-treated mice, a model of oxidative stress in Parkinson's disease
252. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
253. Protein nitration in Parkinson's disease
254. Oxidative stress: Free radical production in neural degeneration
255. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
256. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
257. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease
258. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
259. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus
260. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
261. Glutathione-related enzymes in brain in Parkinson's disease
262. Platelet mitochondrial function in Parkinson's disease
263. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects
264. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease
265. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease
266. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
267. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration
268. Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat
269. Experimental models of Parkinson's disease: Insights from many models
270. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis
271. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
272. Wild-type but not Parkinson's disease-related Ala-53 → The mutant α-synuclein protects neuronal cells from apoptotic stimuli
273. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity
274. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease
275. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: Studies on Parkinson's and incidental Lewy body disease
276. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
277. Multiple system atrophy: A sporadic synucleinopathy
278. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy
279. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not decrease oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologous monkeys
280. Alzheimer's disease: Genes, proteins and therapy
281. Free radical-mediated disruption of cellular ion homeostasis, mitochondrial dysfunction and neuronal degeneration in sporadic and inherited Alzheimer's disease
282. Prospects for pharmacological intervention in Alzheimer disease
283. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β-peptide (1-42)
284. The toxicity in vitro of β-amyloid protein
285. Overexpression of glutathione peroxidase increases the resistance of neuronal cells to Aβ-mediated neurotoxicity
286. SOD I rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein
287. Amyloid β-peptides do not form peptide-derived free radicals spontaneously but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides
288. 2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo
289. Oxidative modification of creatine kinase BB in Alzheimer's disease brain
290. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neurotic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients
291. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease
292. Evidence of neuronal oxidative damage in Alzheimer's disease
293. Increased nuclear DNA oxidation in the brain in Alzheimer's disease
294. 2-isoprostane concentration in probable Alzheimer's disease
295. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders
296. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease
297. 2d-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity
298. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease
299. Ultrastructural localization of heme oxygenase-1 to the neurofibrillary pathology of Alzheimer disease
300. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain
301. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation
302. Prevention of β-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
303. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
304. Binding of amyloid beta protein to the 20 S proteasome
305. Impaired proteasome function in Alzheimer's disease
306. Effect of proteasome inhibition on cellular oxidative damage and antioxidant defences
307. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein
308. 4-Hydroxynonenal-modified amyloid-β peptide inhibits the proteasome: Possible importance in Alzheimer's disease
309. Role of transgenic models for the study of oxidative neurotoxicity in Alzheimer's disease
310. Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies
311. The human DIMINUTO/DWARFI homology Seladin - 1 Confers resistance to Alzheimer's disease - Associated neurodegeneration and oxidative stress
312. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration
313. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals
314. Cu (II) potentiation of Alzheimer Aβ neurotoxicity
315. The possible origin of free radicals from amyloid β peptides in Alzheimer's disease
316. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion
317. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of A beta by zinc
318. Abnormal localization of iron regulatory protein in Alzheimer's disease
319. Redox-active iron mediates amyloid-β toxicity
320. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice
321. Impairment of the ubiquitin-proteasome system by protein aggregation
322. Protein oxidation in response to increased transcriptional or translational errors
323. The importance of inflammatory mechanisms in Alzheimer's disease
324. ·- forming NADPH oxidase in microglia monocytes and neutrophils
325. Anti-inflammatory substances: A new therapeutic option in Alzheimer's disease
326. Prostaglandins as putative neurotoxins in Alzheimer's disease
327. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
328. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease
329. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases
330. Inflammatory glia mediate delayed neuronal damage after ischaemia in the central nervous system
331. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged
332. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease
333. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
334. Dietary supplementation with vitamin E reverses the age-related deficit in long term potentiation in dentate gyrus
335. Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study
336. Regular exercise improves cognitive function and decreases oxidative damage in rat brain
337. Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats
338. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
339. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease
340. Dietary arginine alters time of symptom onset in Huntington's disease transgenic mice
341. Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: A putative mechanism of degeneration
342. Mutant CuZn superoxide dismutase in motor neuron disease
343. Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice
344. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS
345. Oxidative stress and motor neurone disease
346. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase
347. Aberrant copper chemistry as a major mediator of oxidative stress in a human cellular model of amyotrophic lateral sclerosis
348. Release of copper ions from the familial amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutants
349. Site-specific and random fragmentation of Cu,Zn-superoxide dismutase by glycation reaction: Implication of reactive oxygen species
350. Stability of mutant superoxide dismutase-1 associated with familial amyotrophic lateral sclerosis determines the manner of copper release and induction of thioredoxin in erythrocytes
351. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
352. Loss of oxidation-reduction specificity in amyotrophic lateral sclerosis-associated copper-zinc superoxide dismutase mutants
353. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons
354. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis
355. Remarkable increase in cerebrospinal fluid 3-Nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis
356. Increased oxidative damage to DNA in ALS patients
357. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis
358. Effect of an inhibitor of poly (ADP-ribose) polymerase, desmethylselegiline, trientine and lipoic acid in transgenic ALS mice
359. Fullerene-based antioxidants and neurodegenerative disorders
360. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial ALS
361. Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide in familial amyotrophic lateral sclerosis transgenics
362. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis
363. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuropathy (pmn)
364. Examining the evidence about treatment in ALS/MND
365. A double-blind placebo-controlled randomized trial of α-tocopherol (vitamin E) in the treatment of ALS
366. Survival in patients with ALS treated with an array of antioxidants
367. Selegiline is ineffective in a collaborative double-blind placebo-controlled trial for treatment of ALS
368. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice
369. No benefit of dietary restriction on disease onset or progression in amytrophic lateral sclerosis Cu/Zn-superoxide dismutase mutant mice
370. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
371. Gain in functions of mutant Cu,Zn-superoxide dismutases as a causative factor in familial amyotrophic lateral sclerosis: Less reactive oxidant formation but high spontaneous aggregation and precipitation
372. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS
373. Aggregation of ubiquitin and a mutant ALS-linked SOD1 protein correlate with disease progression and fragmentation of the Golgi apparatus
374. Protein precipitation: A common etiology in neurodegenerative disorders?
375. Evaluation of the antioxidant activity of melatonin in vitro
376. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism
377. Glutathione metabolism at the blood-cerebrospinal fluid barrier
378. Marked increase of cysteine levels in many regions of the brain after administration of 2-oxothiazolidine-4-carboxylate
379. Neuroprotection by the metabolic antioxidant alpha-lipoic acid
380. 31P-MRS in a patient with mitochondrial cytopathy
381. The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia
382. A randomized, double-blind, placebo controlled trial of deprenyl and thioctic acid in HIV-associated cognitive impairment
383. Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: Role of antioxidation
384. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: Involvement of the glutathione system
385. Antioxidant properties of nitecapone
386. Recent developments in the drug treatment of Alzheimer's disease
387. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study
388. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study
389. Idebenone: A review of its use in mild to moderate Alzheimer's disease
390. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease
391. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tertbutyl-alpha-phenylnitrone
392. Antioxidants, oxidative stress, and degenerative neurological disorders
393. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
394. Inhibition of NF-kappaB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-N-tert-butylnitrone (PBN)
395. Phenyl N-tert-butyl nitrone forms nitric oxide as a result of its Fe(III)-catalyzed hydrolysis or hydroxyl radical adduct formation
396. Biological spin trapping. II. Toxicity of nitrone spin traps: Dose-ranging in the rat
397. Molecular actions of ebselen: An anti-inflammatory antioxidant
398. Ebselen in acute middle cerebral artery occlusion: A placebo-controlled, double-blind clinical trial
399. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurismal subarachnoid hemorrhage
400. Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischaemia
401. Economic analysis of tirilazad mesylate for aneurismal subarachnoid hemorrhage: Economic evaluation of a phase III clinical trial in Europe and Australia
402. Tirilazad mesylate in acute ischemic stroke: A systematic review
403. Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants
404. Neuroprotective effects of the novel brain-penetrating antioxidant U-101033E and the spin-trapping agent alpha-phenyl-N-tert-butyl nitrone (PBN)
405. Novel cerebroprotective agents with central nervous system stimulating activity 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxy-indan derivatives
406. Free radical scavenger OPC-14117 attentuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum
407. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease
408. Safety tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment
409. Chronic exposure to MPTP as a primate model of progressive parkinsonism: A pilot study with a free radical scavenger
410. Protective effect of a novel free radical scavenger, OPC-14117, on Wobbler mouse motor neuron disease